Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors".